



Authorised Use

The Ministry of Public Health in State of Qatar (MOPH) has issued a Conditional Registration Approval for PAXLOVID for the treatment of COVID 19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID 19.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The product information linked to the QR Code on the product pack has the latest updated product information approved in your country, which may be more up to date than the paper leaflet.

[Read the PAXLOVID™ Summary of
Product Characteristics](#)

